Committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. $EYPT
Joined March 2013
- Tweets 2,524
- Following 1,693
- Followers 1,467
- Likes 306
677 Photos and videos
Pinned Tweet
Feb 17
When it comes to matters of sight, innovation is our vision.
We’re advancing a potential novel multi-mechanism of action for wet AMD and DME - the largest retinal disease markets where there is a significant need for new therapeutic options.
See more on our programs: eyepoint.bio/our-programs/?u…
1
3
300
Jun 11
As summer begins, it’s important to remember that protecting your eyes is just as important as protecting your skin. Research shows sun exposure is connected to the development of AMD.
At EyePoint, we’re advancing potential therapies for retinal diseases, including wet AMD.
eyepoint.bio/our-programs/
1
25
Jun 8
We’re heading to Miami! Members of our management team will join a fireside chat tomorrow at the 47th Annual @GoldmanSachs Global Healthcare Conference.
Tune in here: event.webcasts.com/starthere…
1
47
Jun 4
June is #MensHealthMonth.
At EyePoint, we're advancing potential therapies for serious retinal diseases like DME to improve patient outcomes.
Learn more here: eyepoint.bio/our-programs/
1
50
Jun 2
Tomorrow, members of our management team will join a fireside chat at the 2026 @Jefferies Global Healthcare Conference in New York.
Catch the live webcast here: event.summitcast.com/view/Ng…
1
56
May 29
Our President & CEO, Jay S. Duker, M.D., was recently featured in @RetinaToday's ‘Then and Now’ spotlight where he discusses the evolution of OCT, a non-invasive retina imaging tool that has transformed eye care over the past 20 years.
Read the full article to see what he thinks is coming next for the technology: retinatoday.com/articles/202…
2
60
May 26
Discovery is only the beginning.
Watch the video to learn how we’re translating innovation into therapies for patients living with serious retinal diseases in our Northbridge, MA manufacturing facility. ➡️
1
4
97
May 14
Another positive milestone for EyePoint: The Independent Data Safety Monitoring Committee (DSMC) has reaffirmed its support for our Phase 3 wet AMD trials, with LUGANO and LUCIA progressing on schedule.
📈 Topline data expected beginning mid‑2026.
👉 Read more: investors.eyepoint.bio/news-…
1
77
May 6
#InvestorNews: #EYPT reports Q1 2026 financial results and highlights recent corporate developments.
See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: investors.eyepoint.bio/news-…
1
54
Apr 29
Our pivotal Phase 3 clinical programs focus on the two largest retinal disease markets: wet AMD and DME. Both are designed by conducting recognized non-inferiority trials for potential global regulatory and commercial success.
Swipe to learn more ➡️
eyepoint.bio/our-programs/?u…
75
Apr 14
Wet AMD remains a leading cause of vision loss. TKIs, like our lead investigational therapy, have the potential to reduce the need for frequent follow-up visits, while improving patient outcomes.
See the story in @OPH360:
ophthalmology360.com/retina/…
1
61
Mar 30
On this #NationalDoctorsDay, we proudly honor the exceptional principal investigators driving our pivotal Phase 3 clinical programs in wet AMD and DME. eyepoint.bio/our-programs/?u…
1
71
Mar 18
Even with current anti-VEGF treatments, many people living with DME still face ongoing vision loss, underscoring the critical need for more durable therapies that also address inflammation.
Learn more about our pivotal Phase 3 program: eyepoint.bio/our-programs/?u…
1
107
Mar 4
#InvestorNews: #EYPT reports Q4 and full-year 2025 financial results and highlights recent corporate developments.
See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: investors.eyepoint.bio/news-…
1
114
Mar 2
$EYPT announces first patient in Phase 3 DME clinical trials.
🔎The only sustained release TKI in Phase 3 clinical trials for DME
2️⃣ global, non-inferiority clinical trials, COMO & CAPRI
📈 Topline data expected 2H27
👉 Read more: investors.eyepoint.bio/news-…
2
198
Feb 25
Wet AMD is the leading cause of vision loss and irreversible blindness in people over 50.
This #AMDAwarenessMonth, #EYPT partners with @PBC_savingsight, reinforcing our commitment to improving vision and reducing the treatment burden for patients and caregivers.
preventblindness.org/2026-am…
2
105
Feb 18
$EYPT welcomes Michael Campbell as CCO! With 30 years of commercial leadership and a proven record of product launches, he will be instrumental as we work to potentially bring the first sustained release TKI to patients.
Read more: investors.eyepoint.bio/news-…
1
1
217
Feb 12
Team #EYPT kicked off January with impactful meetings nationwide. Thank you to the host organizations for creating spaces to share updates on our #WetAMD and DME clinical progress and learn from the latest innovations shaping the field.
eyepoint.bio/ ?utm_source=…
2
135